AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34459702 — intervention group
Group type: COMPARATOR
Intervention: Rituximab 375 mg/m2 every 8 weeks for 2 years (arm B)
Number of subjects: 146
Study 34459702 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab-tiuxetan (arm A)
Number of subjects: 146
Study 34459702 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (arm B)
Number of subjects: 146
Study 33765549 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga for 4 weeks
Number of subjects: 79
Study 33765549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 79
Study 34243616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fixed-dose combination (FDC) of acetaminophen 1000 mg + ibuprofen 300 mg administered 6-hourly as a 5 min infusion for 48 hours to 5 days
Number of subjects: 232
Study 32703005 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows (HB)
Number of subjects: 27
Study 33431219 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary artery cannulation
Number of subjects: 111
Study 33431219 — intervention group
Group type: COMPARATOR
Intervention: Innominate artery cannulation
Number of subjects: 111
Study 33706319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging therapy (BT)
Number of subjects: 623
Study 33706319 — intervention group
Group type: COMPARATOR
Intervention: Primary mechanical thrombectomy (PMT)
Number of subjects: 623
Study 32797236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin (40 μg)
Number of subjects: 240
Study 32797236 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol (15 mg/kg)
Number of subjects: 240
Study 34265224 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 66
Study 34265224 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 66
Study 34265224 — intervention group
Group type: COMPARATOR
Intervention: Reference (control)
Number of subjects: 66
Study 32043426 — intervention group
Group type: EXPERIMENTAL
Intervention: arthroscopic microfracture plus intra‐articular injection of HA and haMPCs
Number of subjects: 30
Study 32043426 — intervention group
Group type: EXPERIMENTAL
Intervention: arthroscopic microfracture and intra‐articular injection of HA
Number of subjects: 30
Study 32043426 — intervention group
Group type: COMPARATOR
Intervention: arthroscopic microfracture group and normal saline injection
Number of subjects: 30
Study 35941694 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 anatomically varying cases in a VR simulator
Number of subjects: 24
Study 35941694 — intervention group
Group type: COMPARATOR
Intervention: 12 identical cases in a VR simulator (Control group)
Number of subjects: 24
Study 34474267 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous (IV) metoclopramide
Number of subjects: 108
Study 34474267 — intervention group
Group type: COMPARATOR
Intervention: 30 mg intravenous (IV) ketorolac
Number of subjects: 108
Study 616121600 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (Raxone) 150 mg tablets
Number of subjects: 50
Study 34557985 — intervention group
Group type: EXPERIMENTAL
Intervention: OTee HORSPLAY (occupational therapy in an equine environment) for 10 weeks
Number of subjects: 24
Study 34557985 — intervention group
Group type: EXPERIMENTAL
Intervention: OTee HORSPLAY (occupational therapy in an equine environment)
Number of subjects: 24
Study 34557985 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (occupational therapy in a garden)
Number of subjects: 24
Study 34006542 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 mg subcutaneous injection)
Number of subjects: 0
Study 34006542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36396069 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Smoking Cessation Approach to Promote Empowerment (ESCAPE) intervention
Number of subjects: 250
Study 36396069 — intervention group
Group type: COMPARATOR
Intervention: Standard care (brief advice, referral to a quit line, and a lung cancer screening decision-aide)
Number of subjects: 250
Study 33571464 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training
Number of subjects: 168
Study 33571464 — intervention group
Group type: COMPARATOR
Intervention: Limited training
Number of subjects: 168
Study 33571464 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 33407963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative computed tomography
Number of subjects: 42
Study 33407963 — intervention group
Group type: COMPARATOR
Intervention: Matched pair analysis without pre-operative computed tomography
Number of subjects: 42
Study 36125055 — intervention group
Group type: COMPARATOR
Intervention: Continuous paliperidone palmitate (PP) for 18 months (PP-PP)
Number of subjects: 181
Study 36125055 — intervention group
Group type: COMPARATOR
Intervention: Initial oral antipsychotic (OAP) switched to PP after 9 months (OAP-PP)
Number of subjects: 181
Study 32076854 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 60
Study 32076854 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 35698094 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly screening + symptomatic testing
Number of subjects: 16
Study 35698094 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic testing only
Number of subjects: 16
Study 32372281 — intervention group
Group type: EXPERIMENTAL
Intervention: Popliteus Bypass (Group PB; n=9)
Number of subjects: 18
Study 32372281 — intervention group
Group type: COMPARATOR
Intervention: Larson technique (Group FS; n=9)
Number of subjects: 18
Study 33476593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles)
Number of subjects: 719
Study 33476593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with two cycles of chemotherapy
Number of subjects: 719
Study 33476593 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (every 3 weeks for four cycles)
Number of subjects: 719
Study 33476593 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 719
Study 35419778 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG; exercise plus standard medical care)
Number of subjects: 84
Study 35419778 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; standard medical care)
Number of subjects: 84
Study 33756521 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) at HT7 points for 4 weeks
Number of subjects: 179
Study 33756521 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene instruction (SHI)
Number of subjects: 179
Study 33756521 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA)
Number of subjects: 179
Study 35750724 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (rehearsal) - printouts with images of risks and handwritten descriptions
Number of subjects: 0
Study 35750724 — intervention group
Group type: COMPARATOR
Intervention: Group B (audio-visual presentation) - PowerPoint presentation
Number of subjects: 0
Study 35750724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 34623788 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 1600
Study 34623788 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1600
Study 32169403 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram added to clinician-determined antipsychotic treatment
Number of subjects: 89
Study 32169403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 36137629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 0
Study 36137629 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 0
Study 36137629 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 33721696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5.0 μg)
Number of subjects: 24
Study 33721696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32251031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Morphine
Number of subjects: 134
Study 32251031 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal Hydromorphone
Number of subjects: 134
Study 35441772 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 16
Study 35441772 — intervention group
Group type: COMPARATOR
Intervention: Control (other hand)
Number of subjects: 16
Study 34657589 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT (Mpepu Study)
Number of subjects: 4010
Study 34657589 — intervention group
Group type: COMPARATOR
Intervention: Cohort Study (Maikaelelo Study)
Number of subjects: 4010
Study 33819363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clubs (24 clubs) received feedback letters regarding staff sales behaviour and awareness building activities.
Number of subjects: 50
Study 33819363 — intervention group
Group type: COMPARATOR
Intervention: Comparison clubs (22 clubs) did not receive the intervention.
Number of subjects: 50
Study 32434243 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 160 mg trimethoprim combined with 800 mg sulfamethoxazole three times a week for 12 months (placebo-controlled double-blind study)
Number of subjects: 20
Study 32434243 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 20
Study 36130858 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minutes of choir singing
Number of subjects: 30
Study 36130858 — intervention group
Group type: COMPARATOR
Intervention: Standard voice use (one-on-one conversation, no singing)
Number of subjects: 30
Study 32559413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin supplementation
Number of subjects: 0
Study 32559413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33966329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations for estimating body weight in females aged 65-79 years using height, MUAC, WC, CC, and TST.
Number of subjects: 1456
Study 33966329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations for estimating body weight in females aged ≥ 80 years using height, MUAC, WC, CC, and TST.
Number of subjects: 1456
Study 33966329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations for estimating body weight in males aged 65-79 years using height, MUAC, WC, CC, and TST.
Number of subjects: 1456
Study 33966329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction equations for estimating body weight in males aged ≥ 80 years using height, MUAC, WC, CC, and TST.
Number of subjects: 1456
Study 32367737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-recruiters
Number of subjects: 96
Study 32367737 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-recruiters
Number of subjects: 96
Study 32367737 — intervention group
Group type: COMPARATOR
Intervention: Non-recruiters and low-recruiters
Number of subjects: 96
Study 32367737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment results
Number of subjects: 96
Study 32367737 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment timing
Number of subjects: 96
Study 34959148 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg misoprostol
Number of subjects: 211
Study 34959148 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg misoprostol
Number of subjects: 211
Study 33320019 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 0
Study 33320019 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 10 mg
Number of subjects: 0
Study 33320019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (50 grams)
Number of subjects: 0
Study 33320019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35428739 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical intervention (MSIG)
Number of subjects: 47
Study 35428739 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (CG1)
Number of subjects: 47
Study 35428739 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (CG2)
Number of subjects: 47
Study 33960676 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic terpolymer (T1) skin protectant
Number of subjects: 84
Study 33960676 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide (T2) skin protectant
Number of subjects: 84
Study 33960676 — intervention group
Group type: COMPARATOR
Intervention: Disposable body wipes and zinc oxide protectant (Control)
Number of subjects: 84
Study 32476617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 17
Study 32476617 — intervention group
Group type: COMPARATOR
Intervention: Control VNS
Number of subjects: 17
Study 32476617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS (after crossover from Control VNS)
Number of subjects: 17
Study 93045359 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 21
Study 93045359 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 21
Study 35784544 — intervention group
Group type: EXPERIMENTAL
Intervention: NIFI group (using autofluorescence and indocyanine green fluorescence imaging)
Number of subjects: 180
Study 35784544 — intervention group
Group type: COMPARATOR
Intervention: Control group (naked eye identification)
Number of subjects: 180
Study 35784544 — intervention group
Group type: EXPERIMENTAL
Intervention: NIFI group
Number of subjects: 180
Study 35784544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 35784544 — intervention group
Group type: EXPERIMENTAL
Intervention: NIFI group (with at least one well‐perfused PG)
Number of subjects: 180
Study 32046747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol supplementation of 150 mg for 10 days
Number of subjects: 0
Study 32046747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (BCVA) and central subfield thickness (CST) correlation for ME from RVO
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (BCVA) and central subfield thickness (CST) correlation for DME
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (BCVA) and central subfield thickness (CST) correlation for ME from NIU
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline to 24 weeks for BCVA and CST for ME from RVO
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline to 24 weeks for BCVA and CST for DME
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from baseline to 24 weeks for BCVA and CST for ME from NIU
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Central subfield EZ grades and mean BCVA
Number of subjects: 1063
Study 33130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in BCVA at 24 weeks for eyes with normal baseline central subfield EZ
Number of subjects: 1063
Study 35801750 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior real-time fluoroscopy
Number of subjects: 200
Study 35801750 — intervention group
Group type: COMPARATOR
Intervention: Lateral real-time fluoroscopy
Number of subjects: 200
Study 34197227 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 (peripheral chemoreceptor inhibition)
Number of subjects: 19
Study 34197227 — intervention group
Group type: COMPARATOR
Intervention: 21% O2 (control session)
Number of subjects: 19
Study 33310452 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 13079
Study 33310452 — intervention group
Group type: COMPARATOR
Intervention: Schizophrenia patients
Number of subjects: 13079
Study 33310452 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 13079
Study 33021477 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg subcutaneous injection
Number of subjects: 17
Study 35796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual informed by autofluorescence imaging
Number of subjects: 56
Study 35796769 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone (control)
Number of subjects: 56
Study 34374108 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60mg daily for 6 weeks (5 weeks full dose and 1 week taper)
Number of subjects: 68
Study 34374108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 33121372 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 µg
Number of subjects: 499
Study 33121372 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 µg
Number of subjects: 499
Study 33121372 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 µg
Number of subjects: 499
Study 34449495 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison-based approach
Number of subjects: 126
Study 34449495 — intervention group
Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 126
Study 32165813 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Activity (GA)
Number of subjects: 58
Study 32165813 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Activity with Daily-Monitored-Walking (GAMW)
Number of subjects: 58
Study 32165813 — intervention group
Group type: COMPARATOR
Intervention: Comparison between GA and GAMW
Number of subjects: 58
Study 32880214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 0
Study 32880214 — intervention group
Group type: COMPARATOR
Intervention: Moderate continuous training
Number of subjects: 0
Study 35187867 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (moderate-Ex) for 24 weeks
Number of subjects: 50
Study 35187867 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity exercise (low-Ex) for 24 weeks
Number of subjects: 50
Study 34444779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (500 mL/d; 27% cranberry juice)
Number of subjects: 40
Study 34444779 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 40
Study 32087269 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian Diabetic Risk Score (IDRS)
Number of subjects: 240000
Study 36445862 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial randomized response technique
Number of subjects: 0
Study 36445862 — intervention group
Group type: COMPARATOR
Intervention: Existing randomized response techniques
Number of subjects: 0
Study 33527566 — intervention group
Group type: EXPERIMENTAL
Intervention: G_2D
Number of subjects: 16
Study 33527566 — intervention group
Group type: EXPERIMENTAL
Intervention: G_4D
Number of subjects: 16
Study 33527566 — intervention group
Group type: EXPERIMENTAL
Intervention: G_7D
Number of subjects: 16
Study 33527566 — intervention group
Group type: COMPARATOR
Intervention: G_Control
Number of subjects: 16
Study 33046527 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without recurrent AT/AF
Number of subjects: 518
Study 33046527 — intervention group
Group type: COMPARATOR
Intervention: Patients with recurrent AT/AF
Number of subjects: 518
Study 33046527 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 518
Study 34424347 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh sacrohysteropexy (LSH)
Number of subjects: 101
Study 34424347 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with apical suspension (VH)
Number of subjects: 101
Study 34737281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab with cryoablation
Number of subjects: 29
Study 34737281 — intervention group
Group type: COMPARATOR
Intervention: Tremelimumab without cryoablation
Number of subjects: 29
Study 34737281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Tremelimumab with and without cryoablation)
Number of subjects: 29
Study 35289377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory block testing from anesthetized area to nonanesthetized area
Number of subjects: 31
Study 35289377 — intervention group
Group type: COMPARATOR
Intervention: Sensory block testing from nonanesthetized area to anesthetized area
Number of subjects: 31
Study 32075686 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Only group - ADRD screening at baseline and disclosure of results, with positive-screen participants receiving a list of local resources for diagnostic follow-up.
Number of subjects: 1800
Study 32075686 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Plus group - ADRD screening at baseline with disclosure of results, positive-screen participants referred to a dementia collaborative care program for diagnostic evaluation and potential care.
Number of subjects: 1800
Study 32075686 — intervention group
Group type: COMPARATOR
Intervention: Control group - No screening.
Number of subjects: 1800
Study 32075686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Screening Only and Screening Plus groups.
Number of subjects: 1800
Study 32075686 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Only versus Screening Plus groups.
Number of subjects: 1800
Study 33528914 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg daily
Number of subjects: 47
Study 33528914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 32077553 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of IV acetaminophen + 1 mg of IV hydromorphone
Number of subjects: 162
Study 32077553 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 1 mg of IV hydromorphone
Number of subjects: 162
Study 36763995 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam-alfentanil
Number of subjects: 161
Study 36763995 — intervention group
Group type: COMPARATOR
Intervention: Propofol-alfentanil
Number of subjects: 161